• Join
  • Login
  • Contact

Search abstracts

In silico design and validation of novel cyclin dependent kinase (DC) receptor inhibitors, using the palbociclib scaffold as a lead for the management of breast cancer

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: APS-080
  • By: SHOEMAKE, Claire ()
  • Co-author(s): Mr Andrew Felice, Pharmacy
    Dr Claire Shoemake, Senior Lecturer
  • Abstract:

    Palbociclib has been shown to disrupt tumour proliferation in locally advanced and metastatic breast cancer by inhibiting activity propagated by the homologous enzymes Cyclin Dependent Kinase receptors 4 and 6 (CDK4/6). Despite the therapeutic and prognostic effectiveness of Palbociclib, research shows that prolonged periods of exposure to

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses